Prostate Cancer Outcomes: An International Registry to Improve Outcomes in Men With Advanced Prostate Cancer (IRONMAN) (IRONMAN)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03151629 |
Recruitment Status :
Recruiting
First Posted : May 12, 2017
Last Update Posted : January 6, 2021
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Our intent is to establish the International Registry to Improve Outcomes in Men with Advanced Prostate Cancer (IRONMAN) as a prospective, international cohort of minimum 5,000 men with advanced cancer, including men with mHSPC and M0/M1 CRPC. The goal is to establish a population-based registry and recruit patients across academic and community practices from Australia, Brazil, Canada, Ireland, Sweden, Switzerland, the United Kingdom (UK), and the US. Target accrual number and number of participating sites are subject to change based on accrual, funding, and interest in participation by other international sites. This cohort study will facilitate a better understanding of the variation in care and treatment of advanced prostate cancer across countries and across academia and community based practices.
Detailed data will be collected from patients at study enrollment and then during follow-up, for a minimum of three years. Patients will be followed prospectively for overall survival, clinically significant adverse events, comorbidities, changes in cancer treatments, and PROMs.
PROMs questionnaires will be collected at enrollment, every three months for the first and second year then every six months.
Physician Questionnaires will be collected from all participating sites at patient enrollment, time of first change in treatment and/or one year follow-up, at each subsequent change of treatment, and discontinuation of treatment.
As such, this registry will help identify the treatment sequences or combinations that optimize overall survival and PROMs for men with mHSPC and M0/M1 CRPC. By collecting blood at enrollment, time of first change in treatment and/or one year follow-up (plasma, cell free DNA, buffy coat / RNA), this registry will further identify and validate molecular phenotypes of disease that predict response and resistance to specific therapeutics. Additionally, every effort will be made to collect blood specimen at each subsequent change in treatment. When feasible, existing tumor tissue may be collected for correlation with described blood based studies. All samples will be used for future research. This cohort study will provide the research community with a unique biorepository to identify biomarkers of treatment response and resistance.
Condition or disease | Intervention/treatment |
---|---|
Prostate Cancer | Other: Standard of Care |
Study Type : | Observational [Patient Registry] |
Estimated Enrollment : | 5000 participants |
Observational Model: | Cohort |
Time Perspective: | Prospective |
Target Follow-Up Duration: | 5 Years |
Official Title: | Prostate Cancer Outcomes: An International Registry to Improve Outcomes in Men With Advanced Prostate Cancer (IRONMAN) |
Actual Study Start Date : | July 21, 2017 |
Estimated Primary Completion Date : | January 2029 |
Estimated Study Completion Date : | January 2029 |

Group/Cohort | Intervention/treatment |
---|---|
Castrate Resistant Prostate Cancer |
Other: Standard of Care
Drugs routinely administered for metastatic prostate cancer per local standard. |
Hormone Sensitive Prostate Cancer |
Other: Standard of Care
Drugs routinely administered for metastatic prostate cancer per local standard. |
- Practice Patterns [ Time Frame: 5 years ]To describe the practice patterns of therapeutic agents for treatment of advanced prostate cancer internationally

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 21 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | Male |
Gender Based Eligibility: | Yes |
Gender Eligibility Description: | Men |
Accepts Healthy Volunteers: | No |
Sampling Method: | Non-Probability Sample |
Metastatic hormone sensitive prostate cancer (mHSPC): Prostate cancer patients diagnosed with histologically confirmed cancer with radiological evidence of metastatic disease and on ADT for no more than 90 days.
Castration resistant prostate cancer (CRPC): Prostate cancer patients (with or without radiological evidence of metastatic disease) with a confirmed rising PSA (at least two measures) while on ADT or orchiectomy or castrate level of testosterone as determined by investigator.
Prostate cancer patients with mixed histological types may participate in this Registry.
• Willing and able to provide written informed consent and privacy authorization for the release of personal health information.
NOTE: Privacy authorization may be either included in the informed consent or obtained separately.
- Males 21 years of age and above
- Histological or cytological confirmed prostate adenocarcinoma from TRUS biopsy, radical prostatectomy or TURP Or Documented histopathology or cytopathology of prostate adenocarcinoma from a biopsy of a metastatic site Or Metastatic disease typical of prostate cancer (i.e., involving bone or pelvic lymph nodes or para-aortic lymph nodes) AND a serum concentration of PSA >20ng/mL
- No previous diagnosis of a second, non-prostate malignancy that requires additional systemic therapy except cancer in situ of bladder and basal cell cancer of skin

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03151629
Contact: Jacob Vinson | 646-888-0421 | pcctcironmanregistry@mskcc.org |

Principal Investigator: | Daniel George, MD | Duke Cancer Institute | |
Principal Investigator: | Lorelei Mucci, ScD | Harvard School of Public Health | |
Principal Investigator: | Phillip Kantoff, MD | Memorial Sloan Kettering Cancer Center |
Responsible Party: | Prostate Cancer Clinical Trials Consortium |
ClinicalTrials.gov Identifier: | NCT03151629 |
Other Study ID Numbers: |
c16-170 |
First Posted: | May 12, 2017 Key Record Dates |
Last Update Posted: | January 6, 2021 |
Last Verified: | September 2020 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Prostatic Neoplasms Genital Neoplasms, Male Urogenital Neoplasms |
Neoplasms by Site Neoplasms Prostatic Diseases |